Compare NUVL & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | ENS |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | United States | United States |
| Employees | N/A | 9200 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | 2021 | 2004 |
| Metric | NUVL | ENS |
|---|---|---|
| Price | $123.40 | $221.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 3 |
| Target Price | $134.75 | ★ $193.00 |
| AVG Volume (30 Days) | ★ 2.5M | 425.1K |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 7.70 |
| Revenue | N/A | ★ $216,125,000.00 |
| Revenue This Year | N/A | $4.49 |
| Revenue Next Year | $1,239.49 | $3.41 |
| P/E Ratio | ★ N/A | $29.42 |
| Revenue Growth | N/A | ★ 15.85 |
| 52 Week Low | $71.14 | $82.45 |
| 52 Week High | $123.62 | $244.30 |
| Indicator | NUVL | ENS |
|---|---|---|
| Relative Strength Index (RSI) | 66.60 | 46.46 |
| Support Level | $97.71 | $216.71 |
| Resistance Level | N/A | $244.30 |
| Average True Range (ATR) | 4.37 | 9.79 |
| MACD | 1.97 | -2.58 |
| Stochastic Oscillator | 99.39 | 12.59 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, New Ventures, and Specialty.